MedTrace Logo

Symptom-inhibited Fentanyl Induction

NCT05905367 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-03-16

No results posted yet for this study

Summary

The goal of this clinical trial is to test a treatment strategy for individuals with opioid use disorder (OUD) who use fentanyl. Participants will receive medically-administered doses of intravenous (IV) fentanyl at intervals until they are comfortable and do not have withdrawal symptoms. They then will be given opioid agonist therapy (OAT) once daily by mouth, which is the current standard treatment for OUD. In this trial, each participant's starting dose of OAT will be tailored to meet their opioid needs, based on the amount of IV fentanyl they received.

The main questions this trial aims to answer are:

* Is the IV fentanyl protocol feasible and safe for use in a community clinic setting?
* Will the protocol result in higher-than-standard starting doses of OAT? Are these doses safe, and will they enable participants to stay on OAT for a longer time?

Conditions

Interventions

DRUG

Fentanyl

Symptom-inhibited IV fentanyl induction

DRUG

Methadone

Opioid agonist therapy (OAT) with methadone at starting doses established by symptom-inhibited IV fentanyl induction

DRUG

Slow-release oral morphine

Opioid agonist therapy (OAT) with SROM at starting doses established by symptom-inhibited IV fentanyl induction

Sponsors & Collaborators

  • Pouya Azar

    lead OTHER

Principal Investigators

  • Pouya Azar, MD · University of British Columbia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-29
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05905367 on ClinicalTrials.gov